Decibel Therapeutics

37 articles with Decibel Therapeutics

• Decibel Therapeutics Announces DB-020 Has Been Granted Fast Track Designation by the U.S. Food and Drug Administration

  12/17/2020

  Decibel Therapeutics , a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that their clinical product candidate, DB-020, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). DB-020 is an investigational therapy for the prevention of cisplatin-induced hearing loss, a serious and debi

• Decibel Therapeutics Announces $82M Series D Financing to Advance Gene Therapies to Restore Hearing and Balance

  11/9/2020

  Proceeds support advancement of lead gene therapy programs and accelerate development of therapeutics to restore functional hair cells in the inner ear

• Decibel Therapeutics Announces Exclusive Licensing Agreements for Hearing Loss Gene Therapy Technology

  11/2/2020

  Decibel Therapeutics , a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, today announced exclusive license agreements with the University of Florida (UF) and the University of California, San Francisco (UCSF) for an adeno-associated virus (AAV) gene therapy technology designed to restore hearing to individuals with profound, congenital hearing loss c

• 

  An Overview of Citi’s 15th Annual BioPharma Conference 2020 Boston

  9/9/2020

  Like almost all conferences this year, Citi’s 15th Annual BioPharma Conference 2020 is being held virtually.

• Decibel Therapeutics to Present at Citi's 15th Annual BioPharma Virtual Conference

  9/2/2020

  Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, today announced that Laurence Reid Ph.D., Chief Executive Officer of Decibel, will present at Citi's 15th Annual BioPharma Virtual Conference on Tuesday, September 8, 2020 at 1:10pm ET. About Decibel Therapeutics Decibel Therapeutics is a clinical-stage biotechnology co

• Decibel Therapeutics to Present at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

  5/11/2020

  Decibel Therapeutics to Present at the 23 rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

• Decibel Therapeutics Publishes Results from Early-Stage Study of Therapy Designed to Prevent Hearing Loss Associated with Cisplatin Chemotherapy

  3/26/2020

  Decibel Therapeutics , today announced that Phase 1a trial results demonstrating the safety and tolerability of its lead candidate, DB-020, have been published in the peer-reviewed journal Investigational New Drugs . DB-020 is being developed for the prevention of cisplatin-induced hearing loss. The

• 

  BioSpace Movers and Shakers, Jan. 31

  1/31/2020

  Pharma and biotech companies strengthen their leadership teams and boards with this week's Movers & Shakers.

• Decibel Therapeutics Announces Strategic Research Focus on Regenerative Medicine for the Inner Ear

  1/29/2020

  Decibel Therapeutics, a development-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, today announced a new strategic research focus on regenerative medicine approaches for the inner ear

• Decibel Therapeutics Announces Leadership Transition

  1/29/2020

  Decibel Therapeutics, a development-stage biotechnology company advancing novel therapeutics for hearing loss and balance disorders, today announced that industry veteran Laurence Reid, Ph.D., has been appointed as Decibel’s acting chief executive officer, bringing deep experience in biotech company building.

• Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference

  1/24/2020

  Decibel Therapeutics, a development-stage biotechnology company creating novel therapeutics for hearing loss and balance disorders, will present new findings from several of their drug discovery and development programs at the 43rd annual meeting of the Association for Research in Otolaryngology, which is being held from January 25-29 in San Jose, CA.

• Decibel Therapeutics to Provide Corporate Update at Jefferies Gene Therapy Summit

  10/7/2019

  Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, will provide a corporate update at the upcoming Jefferies Gene Therapy Summit in New York City on Tuesday, October 8, 2019 at 9:45 a.m. ET.

• 

  BioSpace Movers and Shakers: Ambys, Decibel, Verona, and More

  6/28/2019

  Biotech and pharma companies tap new members of executive leadership teams and boards.

• Decibel Therapeutics Appoints Healthcare Industry Veteran Christine A. Poon to its Board of Directors

  6/26/2019

  Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, announced the appointment of Christine Poon to its board of directors.

• Decibel Therapeutics Selects 4G Clinical as Preferred IxRS/RTSM Provider

  2/12/2019

   4G Clinical today announced a partnership with Decibel Therapeutics to enable complex trial designs for the development of novel therapies for hearing and balance disorders.

• 

  BioSpace Movers and Shakers: Feb. 8

  2/8/2019

  In this week's edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles.

• Decibel Therapeutics to Present at the Association for Research in Otolaryngology (ARO) Conference

  2/6/2019

  Decibel Therapeutics will showcase capabilities across its inner ear-focused drug discovery and development platform at the 42nd annual mid-winter meeting of the Association for Research in Otolaryngology from February 9-13, 2019.

• Decibel Therapeutics Bolsters Leadership Team with Appointments of Chief Medical Officer and Chief Operating Officer

  2/5/2019

  Decibel Therapeutics today announced the appointment of leading otolaryngologist Dr.

• Decibel Therapeutics and Cocoon Biotech Announce Collaboration to Develop Proprietary Formulations for Delivery of Medicines to the Inner Ear

  1/7/2019

  Decibel Therapeutics and Cocoon Biotech announced a research collaboration to apply Cocoon's proprietary silk fibroin platform to the development of therapeutics for hearing and balance disorders

• 

  Listen up! Researchers Find Key to Regrowing Cells Related to Hearing Loss

  10/16/2018

  Among life on earth, mammals are some of the only creatures that can’t regenerate damaged hearing. Birds, frogs, fish, they all have the ability to regenerate sensory hair cells after they’re damaged.